GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

The $16 billion dollar 'asset swap' deal between GlaxoSmithKline (GSK) and Novartis has been formally completed today, with the UK-headquartered company exchanging its oncology portfolio for the ...

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.